OptimizeRx (NASDAQ:OPRX) Rating Increased to Strong-Buy at B. Riley

B. Riley upgraded shares of OptimizeRx (NASDAQ:OPRX) to a strong-buy rating in a report issued on Wednesday morning, Marketbeat Ratings reports.

Several other research analysts have also recently commented on the company. Lake Street Capital reissued a “buy” rating and set a $11.00 price target on shares of OptimizeRx in a research report on Tuesday, December 24th. Roth Mkm reaffirmed a “buy” rating and issued a $16.00 price objective (down from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Finally, Stephens started coverage on OptimizeRx in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price objective for the company. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, OptimizeRx presently has an average rating of “Moderate Buy” and an average target price of $9.06.

OptimizeRx Stock Performance

Shares of NASDAQ OPRX opened at $7.15 on Wednesday. The stock has a 50 day moving average price of $5.44 and a 200 day moving average price of $5.93. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $14.13. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a market capitalization of $131.71 million, a PE ratio of -5.38 and a beta of 1.31.

Institutional Trading of OptimizeRx

Several hedge funds have recently added to or reduced their stakes in OPRX. SBI Securities Co. Ltd. acquired a new stake in OptimizeRx during the 4th quarter worth approximately $25,000. BNP Paribas Financial Markets increased its stake in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after acquiring an additional 2,414 shares during the period. SG Americas Securities LLC bought a new position in OptimizeRx during the 4th quarter worth $51,000. Wells Fargo & Company MN increased its stake in OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after acquiring an additional 2,797 shares during the period. Finally, Quest Partners LLC increased its stake in OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after acquiring an additional 9,739 shares during the period. 76.47% of the stock is owned by institutional investors and hedge funds.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.